Egyptian International Pharmaceutical Investments (CAI:PHAR) Days Payable : 16.74 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments Days Payable?

Egyptian International Pharmaceutical Investments's average Accounts Payable for the three months ended in Dec. 2023 was E£168 Mil. Egyptian International Pharmaceutical Investments's Cost of Goods Sold for the three months ended in Dec. 2023 was E£917 Mil. Hence, Egyptian International Pharmaceutical Investments's Days Payable for the three months ended in Dec. 2023 was 16.74.

The historical rank and industry rank for Egyptian International Pharmaceutical Investments's Days Payable or its related term are showing as below:

CAI:PHAR' s Days Payable Range Over the Past 10 Years
Min: 14.36 Med: 21.86 Max: 23.73
Current: 23.19

During the past 13 years, Egyptian International Pharmaceutical Investments's highest Days Payable was 23.73. The lowest was 14.36. And the median was 21.86.

CAI:PHAR's Days Payable is ranked worse than
93.76% of 977 companies
in the Drug Manufacturers industry
Industry Median: 86.3 vs CAI:PHAR: 23.19

Egyptian International Pharmaceutical Investments's Days Payable declined from Dec. 2022 (19.26) to Dec. 2023 (16.74). It may suggest that Egyptian International Pharmaceutical Investments accelerated paying its suppliers.

Egyptian International Pharmaceutical Investments Days Payable Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments Days Payable Chart

Egyptian International Pharmaceutical Investments Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

14.36

21.86

23.73

Egyptian International Pharmaceutical Investments Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															19.26	35.90	25.89	19.87	16.74

Competitive Comparison of Egyptian International Pharmaceutical Investments's Days Payable

For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Egyptian International Pharmaceutical Investments's Days Payable Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Egyptian International Pharmaceutical Investments's Days Payable distribution charts can be found below:

* The bar in red indicates where Egyptian International Pharmaceutical Investments's Days Payable falls into.

Egyptian International Pharmaceutical Investments Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Egyptian International Pharmaceutical Investments's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (200.246	+	176.354)	/	2 )	/	2896.344	*	365
=	188.3					/	2896.344	*	365
=	23.73

Egyptian International Pharmaceutical Investments's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (160.147	+	176.354)	/	2 )	/	916.973	*	365 / 4
=	168.2505					/	916.973	*	365 / 4
=	16.74

Egyptian International Pharmaceutical Investments Days Payable Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY

Website

http://www.eipico.com.eg

Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.